Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_3
2
40%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 32 (40.0%)

Trials by Status

recruiting360%
not_yet_recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
not_yet_recruitingphase_1

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

NCT07538154
recruitingphase_3

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

NCT07388602
recruitingphase_3

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07297329
not_yet_recruitingphase_1

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

NCT06774664
recruitingphase_1

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

NCT06252298

Clinical Trials (5)

Showing 5 of 5 trials
NCT07538154Phase 1

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Not Yet Recruiting
NCT07388602Phase 3

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Recruiting
NCT07297329Phase 3

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting
NCT06774664Phase 1

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not Yet Recruiting
NCT06252298Phase 1

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5